Daniel M. Halperin, MD
Medical Oncologist and Clinical Investigator
MD Anderson Cancer Center, Houston, Texas
Daniel M. Halperin, MD, will be the featured guest for Luncheon with the Experts on Thursday, February 25, 2021 from 12 noon to 1 pm, Eastern Time. A medical oncologist and clinical investigator, Dr. Halperin focuses on the development of novel treatments for patients with neuroendocrine tumors (NETs), in addition to providing clinical care to patients with NETs and other gastrointestinal cancers. He leads clinical trials of new drugs for patients with NETs at MD Anderson Cancer Center in Texas, and works with a team of laboratory and population scientists to understand more fully the molecular underpinnings and clinical manifestations of neuroendocrine tumors.
He is also a member of the Neuroendocrine and Adrenal Tumor guideline committee of the National Comprehensive Cancer Network, contributing to evidence-based guidelines for the care of NET patients. Dr. Halperin has a particular interest in the immunology of neuroendocrine tumors and the use of immunotherapy for patients with NETs. As such, he has received peer-reviewed funding from the Neuroendocrine Tumor Research Foundation, as well as a Career Development Award from the American Society of Clinical Oncology, to understand the immunology of NETs and leads a clinical trial of immunotherapy with atezolizumab and bevacizumab for patients with specific rare solid tumors, including two separate cohorts of patients with advanced well-differentiated NETs.
RESOURCES
To make an appointment with Dr. Halperin, click here: https://faculty.mdanderson.org/profiles/daniel_halperin.html
Selected Publications:
- Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors, https://journals.lww.com/pancreasjournal/Fulltext/2020/10000/Differential_Diagnosis_of_Diarrhea_in_Patients.1.aspx
- The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors, https://nanets.net/images/guidelines/2020_NANETS_Guidelines_2020_Surveillance_and_Medical_Management_of_Pancreatic_Neuroendocrine_Tumors.pdf
- Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials (abstract), https://pubmed.ncbi.nlm.nih.gov/32152503/
- Direct costs of carcinoid syndrome diarrhea among adults in the United States, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931008/
- Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246350/
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824320/
- The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444330/
- Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238007/
Clinical Trial, Recruiting:
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2), https://www.clinicaltrials.gov/ct2/show/NCT03972488?term=Daniel+Halperin%2C+MD&cond=neuroendocrine+tumors&cntry=US&draw=2&rank=1
Videos:
- Lutathera Leads Therapeutic Advances in NETs, https://www.onclive.com/view/lutathera-leads-therapeutic-advances-in-nets
- Functional Tumors – Carcinoid Syndrome: Daniel M. Halperin, MD – 2019 LA NET Conference, https://youtu.be/Nc0JXRhcwSE
- NETs Symptoms and Treatments, Dan Halperin, MD; MD Anderson, 2018 NETRF Houston Conference, https://youtu.be/rdJGtr6Zj9k
Social Media:
MD Anderson Cancer Center on Twitter, https://twitter.com/MDAndersonNews
